Illumina Stock Forecast
NASDAQ: ILMNHealth CareMedical SpecialitiesUSD
Market open · Delayed 15 min · as of Oct 8, 3:37 PM ET
ILMN analyst consensus
Consensus (21 analysts)
buy
Avg. price target
$223.85-15.05%
- Strong buy 4
- Buy 7
- Hold 6
- Sell 2
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 21 Wall Street analysts covering Illumina (2026-10-07), 11 rate the stock a buy or strong buy, 6 rate it a hold and 4 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $223.85, with a high estimate of $310.00 and a low estimate of $113.00. The average target implies downside of 15.1% from the current price of $263.52.
The spread between the highest and lowest targets is 174.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ILMN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 19% |
| Buy | 7 | 33% |
| Hold | 6 | 29% |
| Sell | 2 | 10% |
| Strong sell | 2 | 10% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $113.00 | -57.12% |
| Average target | $223.85 | -15.05% |
| High target | $310.00 | +17.64% |